BICARA THERAPEUTICS INC (BCAX) Stock News
NASDAQ:BCAX - Nasdaq - US0554771032 - Currency: USD
BCAX Latest News, Press Relases and Analysis
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising...
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized
A trio of biotech companies’ shares rose in their first trading sessions after they each sold more shares in their respective initial public offerings than they had planned.
Bicara Leads Trio of US Biotech IPOs Raising $703 Million
A trio of biotech companies sold shares in their initial public offerings on Thursday, an encouraging sign for a sector whose new entrants have lately struggled.
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing...